Recent Updates
Recently added Catalysts
ARQT Positive Sentiment Score: 75/100

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Key Takeaway: Arcutis Biotherapeutics, Inc. will present at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. The management team will partake in a fireside chat scheduled for April 8, 2025, at 11:00 am EDT. This participation underscores Arcutis's commitment to addressing significant needs within immuno-dermatology, backed by a robust portfolio that includes three FDA approved products and a variety of pipeline programs. The conference webcasts will be accessible on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcutis is actively participating in the 24th Annual Needham Virtual Healthcare Conference.
  • The company showcases its commitment to addressing urgent needs in immuno-dermatology.
  • Arcutis holds a growing portfolio of three FDA approved products.

Full Press Release Details

WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Details for the company’s participation are as follows:
Fireside Chat Date: Tuesday, April 8, 2025
Fireside Chat Time: 11:00 am EDT
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Amanda Sheldon, Head of Corporate Communications
Latha Vairavan, Vice President, Finance and Corporate Controller

Related Links

Frequently Asked Questions

When is Arcutis participating in the Needham Virtual Healthcare Conference?

Arcutis will participate in the conference from April 7 to 10, 2025.

What time is Arcutis' fireside chat scheduled?

The fireside chat is scheduled for April 8, 2025, at 11:00 am EDT.

How can I access the webcast of the conference?

The webcast can be accessed in the 'Events' section of Arcutis' website.

What is Arcutis Biotherapeutics focused on?

Arcutis focuses on innovative treatments for immune-mediated dermatological diseases.

Does Arcutis have FDA approved products?

Yes, Arcutis has three FDA approved products in its portfolio.

Last updated: Mar 27, 2025